Hypothermic Machine Perfusion Market Size, Share, and Industry Analysis, By Type (Product {Systems and Reagents & Consumables} and Services), By Application (Liver, Heart, Kidney, and Others), By End-user (Hospitals, Transplantation Centers, and Others), and Regional Forecast, 2026-2034

The global hypothermic machine perfusion market size was valued at USD 3.57 billion in 2025. The market is projected to grow from USD 3.82 billion in 2026 to USD 6.6 billion by 2034, exhibiting a CAGR of 7.09% during the forecast period.

Hypothermic machine perfusion (HMP) is utilized in organ transplantation to preserve donor organs through the circulation of a cold preservation solution through the organ. This technique reduces the metabolism of the organ, allowing for better preservation and viability before transplantation. Hypothermic machine perfusion (HMP) reduces cell death by decreasing apoptosis and necrosis, making it a valuable tool for improving organ quality and outcomes in transplantation.

In addition, hypothermic machine perfusion (HMP) offers several benefits over the other preservation methods in organ transplantation. Some of these benefits include improved graft survival, decreased incidence of delayed graft function (DGF), enhanced viability of higher-risk donor organs, active repair & assessment, and continuous perfusion with novel technologies.

The demand for hypothermic machine perfusion technology is significantly expected to be fueled by rising organ transplantation procedures worldwide. For instance, as of January 2024, the U.S. Department of Health & Human Services reported that a total number of 46,632 organ transplants were carried out in 2023, comprising both living and deceased donors. This witnessed an increase in transplantation procedures by 8.7% compared to 2022 and 12.7% compared to 2021.

Furthermore, hypothermic machine perfusion offers a higher ability to maintain organ viability and function than normothermic machine perfusion and traditional cold storage methods. This ability of hypothermic machine perfusion is projected to fuel the demand for its products & services for organ preservation, propelling the market growth during the projection period.

• For instance, in May 2024, according to Bridge to Life Ltd, hypothermic oxygenated machine perfusion provides significantly greater outcomes than ice-box static cold storage (SCS) and normothermic machine perfusion (NMP) for livers awaiting transplantation.

Moreover, the rising incidence of chronic diseases such as fatty liver disease, hepatitis C, glomerulonephritis, and polycystic kidney disease leading to organ failures are expected to fuel the global demand for organ preservation amongst the patients awaiting transplantation. Hypothermic machine perfusion improves the quality and viability of such donor organs prior to their transplantation into a recipient. As a result, its adoption and popularity are growing in several transplant centers and healthcare facilities globally. This is expected to boost market growth in the coming years.

• For instance, as of April 2024, the World Health Organization (WHO) reported that an estimated 50.0 million individuals are currently affected with hepatitis C virus infection, and an estimated 1.2 million new cases occur every year. This is expected to surge the demand for organ preservation prior to liver transplantation, driving the utilization of hypothermic machine perfusion products & services.

The COVID-19 pandemic exerted a slightly negative impact on the hypothermic machine perfusion market. The pandemic led to a decreased rate of organ transplantation due to a reduction in the number of organ donations and the reduced accessibility to healthcare facilities. These factors decreased the demand for hypothermic machine perfusion products & services, leading to slow growth during the COVID-19 outbreak.

• For instance, in April 2022, according to the National Center for Biotechnology Information (NCBI), organ transplantation rates declined by 16.0% in 2020 as compared to 2019. This resulted in decreased adoption of hypothermic machine perfusion technology, thereby decreasing the sales of products & services. This led to a decline in the growth of the hypothermic machine perfusion market during the pandemic.

Segmentation

Key Insights

The report covers the following key insights:

• Number of Organ Transplantation - by Key Countries/Region, 2023
• Technological Advancements in Hypothermic Machine Perfusion
• Key Industry Developments - (Mergers, Acquisitions, and Partnerships)
• Regulatory Overview of Organ Transplantation - by Key Countries/Region
• Impact of COVID-19 on the Market       

Analysis by Type

Based on type, the market is segmented into product and services. The product segment is projected to account for a significant share of the global hypothermic machine perfusion market during the forecast period. This growth is attributed to the growing use of hypothermic machine perfusion products in organ preservation, organ reconditioning, and organ viability assessment. Moreover, this rising demand inspires numerous key companies in the market to focus on research and development of novel products that will result in the introduction of advanced products. This increases its availability and accessibility to hospitals and transplant centers, boosting the segment growth in upcoming years.

• For instance, as of May 2024, LifePort Liver Transporter by Organ Recovery Systems is still under development and not approved for clinical use. Furthermore, this product is in the process of securing the U.S. and European regulatory registrations. Successful clinical results and approval of this product in the U.S. and Europe will expand its usage in kidney preservation and transplantation in the near future.

On the other hand, the services segment is projected to expand at a noteworthy CAGR during the forecast timeframe. This noteworthy growth is attributed to the expansion of organ recovery services by prominent market players across the globe. This expansion of services is expected to boost the demand for hypothermic machine perfusion services, encouraging the key players to focus on offering selective access to organ recovery. This is anticipated to propel the segmental growth in the forthcoming years.

Regional Analysis

To gain extensive insights into the market, Download for Customization

The global market is geographically segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America is expected to hold a significant share of the hypothermic machine perfusion market during the forecast period. The rising geriatric population is expected to boost regional market growth, as old individuals carry a higher risk of organ failure than adults. Moreover, the emphasis on clinical developments regarding hypothermic machine perfusion, leading to the introduction of innovative products in the region, is also expected to boost the market growth. Furthermore, these factors result in the increasing penetration rate of products in the region, which is expected to surge the regional market growth.

• For instance, as of January 2024, the Population Reference Bureau stated that the number of people aged 65 and over is projected to increase from 58.0 million in 2022 to 82.0 million by 2050 in the U.S.

Asia Pacific is projected to grow at a significant CAGR during the forecast timeframe. The rising awareness regarding organ donation in the region is expected to boost the availability of organs to be preserved. This is further anticipated to drive the demand and increase the utilization of hypothermic machine perfusion products & services in the region, driving the market growth. Moreover, government initiatives to support organ transplantation with favorable policies are expected to boost the demand for organ preservation, driving the utilization of hypothermic machine perfusion products in the region.

• For instance, in March 2023, the Government of India worked with the objective of “One Nation, One Policy” for organ donation and transplantation in consultation with the states, diminishing the requirement of domicile for patient registration to receive deceased donor organs. This allowed patients to visit any state for organ transplantation, increasing the ease of availability of organs.

Key Players Covered

The market consists of significant players, such as Organ Recovery Systems, XVIVO, IGL, Bridge to Life Ltd, and Vascular Perfusion Solutions, Inc. The increasing focus of these players on new technologically advanced product launches has been fueling their revenue growth.

Key Industry Developments

• In December 2023, XVIVO, in collaboration with Professor Stig Steen at Igelösa Life Science, developed a product for a new, non-ischemic preservation method, hypothermic oxygenated perfusion (HOPE).
• In February 2022, Vascular Perfusion Solutions, Inc. announced that it received its first donated human heart for research through a partnership with the Texas Organ Sharing Alliance (TOSA). The experiment on this heart successfully achieved a preservation time of 8 hours in its VP.S Encore, a hypothermic machine perfusion device for the heart.
• In February 2021, Vascular Perfusion Solutions, Inc. received FDA approval for its VP.S Encore, an oxygenated perfusion cardiac transport device. This lifesaving technology expanded its reach in the U.S.